

New Agents and Emerging Strategies in the Management of Uterine Sarcomas

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The results of the Phase III GeDDiS trial evaluating gemcitabine/docetaxel versus doxorubicin as first-line therapy for patients with locally advanced or metastatic soft tissue sarcoma demonstrated a statistically significant improvement in _____ with the combination.

 - Progression-free survival
 - Overall survival
 - Quality of life at 12 weeks
 - All of the above
 - None of the above
- Early trials of immune checkpoint inhibitors have demonstrated promising activity in patients with leiomyosarcoma, with objective response rates of 50% or higher.

 - True
 - False
- The Phase III SARCGYN study of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin followed by pelvic radiation therapy compared to radiation therapy alone for patients with localized uterine sarcoma demonstrated a significant advantage in _____ with the addition of chemotherapy.

 - Three-year disease-free survival
 - Three-year overall survival
 - Both a and b
- The mechanism of action of olaratumab involves the inhibition of _____.

 - VEGFR-2
 - PDGFR-alpha
 - PD-1/PD-L1
- According to a retrospective analysis by Nasioudis and colleagues of patients with Stage I uterine sarcoma who underwent hysterectomy with or without oophorectomy and did not receive radiation therapy, ovarian preservation _____ in comparison to oophorectomy in the subset of women with leiomyosarcoma.

 - Significantly improved overall survival
 - Significantly decreased overall survival
 - Was not associated with significantly worse overall survival
- The Phase Ib/II study of doxorubicin with or without olaratumab for patients with unresectable or metastatic soft tissue sarcomas demonstrated a statistically significant improvement in _____ with olaratumab, leading to FDA approval of that agent.

 - Overall survival
 - Objective response rate
 - Both a and b
- The mechanism of action of trabectedin involves _____.

 - Interfering with DNA transcription and DNA repair
 - Inhibiting PDGFR
 - Inhibiting immune checkpoints
- The majority of infusion reactions to olaratumab occur during cycle 1 or 2 of therapy.

 - True
 - False
- Which of the following histologic subtypes of uterine sarcoma is the most common?

 - Endometrial stromal sarcoma
 - Adenosarcoma
 - Leiomyosarcoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

10. A Phase III EORTC study comparing pelvic radiation therapy to observation for patients with Stage I or Stage II uterine sarcoma demonstrated _____ with radiation therapy.
- a. Significantly improved overall survival
 - b. Decreased locoregional recurrence
 - c. Significantly improved progression-free survival